Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
Talphera (Nasdaq: TLPH) will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to discuss its second quarter 2026 financial results and recent business progress.
Rhea-AI Summary
Talphera (Nasdaq: TLPH) will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to discuss its second quarter 2026 financial results and recent business progress. North American participants can dial 1-800-836-8184 and international participants 1-646-357-8785 using conference ID 50873. A live webcast and a 90-day replay will be available via the Upcoming Events page in the Investors section of the Talphera website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TLPH
On Aug 6, the first trading day after this news, TLPH closed 5.93% above the previous close. Argus tracked a peak move of +2.5% during that session. Our momentum scanner recorded 9 alerts for this stock that day.
Data tracked by StockTitan Argus for the Aug 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Information
- Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
- Participant Dial-in (
North America ): 1-800-836-8184 - Participant Dial-in (International): 1-646-357-8785
- Conference ID: 50873
- Webcast Access: Click here
The event can also be accessed in the Upcoming Events page in the Investors section of the Talphera website at www.talphera.com.
A replay of the webcast will be available on the Talphera website for 90 days after the event.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-report-second-quarter-2026-financial-results-on-wednesday-august-12-2026-302844071.html
SOURCE Talphera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.